← Eichor
Condition: Medullary Thyroid Cancer Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Medullary Thyroid Cancer

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Head-to-head Study of 68Ga-MGS5 Versus 68Ga-DOTATATE PET/CT in Patients With Medullary Thyroid Carcinoma
Phase 1 · 1 location(s) · First Affiliated Hospital of Fujian Medical University · NCT06520319Clinical and Genetic Studies in Familial Non-medullary Thyroid Cancer
Phase N/A · 1 location(s) · National Institute of Diabetes and Digestive and Kidney Dise · NCT01109420Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
Phase 1/Phase 2 · 2 location(s) · University of Arizona · NCT0681449668Ga-TCR-FAPI PET/CT Guided Precision Surgery for MTC
NA · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT06277180Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and
Phase 2 · 1 location(s) · Gustave Roussy, Cancer Campus, Grand Paris · NCT07016230Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma
Phase 2 · 1 location(s) · Giuseppe Procopio · NCT06302569Study of Anlotinib in Patients With Advanced Medullary Thyroid Carcinoma
Phase 4 · 19 location(s) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · NCT05830500Patient Decision Aid in Supporting Decision-Making About When to Start or Stop New Drugs, Join Clinical Trials, or Conti
NA · 1 location(s) · M.D. Anderson Cancer Center · NCT03892993Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients
Phase N/A · 3 location(s) · Universidad Nacional Autonoma de Mexico · NCT06523582CTR-FAPI-guided Precision Surgery for Newly Diagnosed MTC
Phase 3 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT07383246Treatment of Advanced Endocrine Tumor With Iindividualized mRNA Neoantigen Vaccine (mRNA-0523-L001)
NA · 1 location(s) · Shanghai Jiao Tong University School of Medicine · NCT06141369Research on the Application of 68Ga-DOTA-CCK-FS PET/CT in MTC
NA · 1 location(s) · Luo Yaping · NCT07138716Phase II Trial of Ubamatamab Alone or in Combination With Cemiplimab in MUC16-Expressing SMARCB1-Deficient Malignancies
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT06444880Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabo
Phase 2 · 582 location(s) · National Cancer Institute (NCI) · NCT03866382Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade
Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT06161532Natural History Study of Children and Adults With Medullary Thyroid Cancer
Phase N/A · 1 location(s) · National Cancer Institute (NCI) · NCT01660984Cultural Adaptation of an Educational Tool in Medullary Thyroid Cancer
Phase N/A · 1 location(s) · M.D. Anderson Cancer Center · NCT07142005Social Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors
Phase N/A · 2 location(s) · University of Southern California · NCT07259304GETNE Registration of Thyroid Cancer
Phase N/A · 1 location(s) · Grupo Espanol de Tumores Neuroendocrinos · NCT03765333Natural History of Medullary Thyroid Cancer to Inform Advanced Disease Management
Phase N/A · 2 location(s) · M.D. Anderson Cancer Center · NCT04216732
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.